PharmaPoint: Painful Diabetic Neuropathy-Global Drug Forecast and Market Analysis to 2026
Region:Global
Product Code:GDHC164PIDR
April 2018
218
About the Report
PharmaPoint: Painful Diabetic Neuropathy-Global Drug Forecast and Market Analysis to 2026
Summary
Painful diabetic neuropathy is a late-stage complication that occurs in patients suffering from diabetes mellitus and is thought to affect up to half of patients with the disease. PDN manifests itself as a variety of syndromes which differ in clinical course, distribution, fibre involvement and, pathophysiology. Symptoms will vary from patient to patient however; the most common pain symptoms are reported to be numbness, tingling, burning, sharp, and dull/ache-like, which are often localized to the extremities, affecting the feet and hands.
Currently, there are only three approved therapies for the treatment of PDN, Pfizer's Lyrica, Eli Lilly's Cymbalta, and Grünenthal's Nucynta ER. Acorda Therapeutics has marketed an 8% capsaicin patch (Qutenza) which is approved for peripheral neuropathic pain and may be used in certain PDN syndromes. Outside of these drugs the market consists of off label use and generics.
GlobalData estimates that drug sales for PDN in 2016 were approximately USD3.1B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to USD7.1B at a CAGR of 8.7%. This growth will be driven by the launch of four late-stage pipeline products. The two highest selling drugs are expected to be ViroMed's VM202 and Daiichi-Sankyo's mirogabalin besylate, which both address some of the unmet needs in the market.
Scope
Overview of PDN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized PDN therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (typical and atypical) forecast from 2016 to 2026.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PDN therapeutics market
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PDN therapy. The most promising candidates in Phase III development are profiled.
Analysis of the current and future market competition in the global PDN therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to-
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global PDN therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PDN therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Scope of the Report
Companies
Pfizer
Grunethal
Daiichi-Sankyo
Depomed
ViroMed
Table of Contents
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Painful Diabetic Neuropathy: Executive Summary
2.1 PDN Market Is Expected to Reach USD7B by 2026
2.2 Partnerships and Licensing Agreements Are the Most Commonly Used Strategy
2.3 Drugs with Improved Safety and Efficacy Profiles Top the Unmet Needs
2.4 Big Opportunities for Companies Willing to Invest In Pathophysiology Research
2.5 Gene Therapy Is a Key Driver of Growth in the Global PDN Market
2.6 What Do the Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Overview
4.2 Classification or Staging Systems
4.3 Etiology and Pathophysiology
4.3.1 Etiology
4.3.2 Pathophysiology
4.4 Symptoms
4.5 Prognosis
4.6 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for PDN (2016-2026)
5.5.1 Total Prevalent Cases of PDN
5.5.2 Age-Specific Total Prevalent Cases of PDN
5.5.3 Sex-Specific Total Prevalent Cases of PDN
5.5.4 Total Prevalent Cases of PDN by Severity of Neuropathy
5.5.5 Total Prevalent Cases of Typical and Atypical PDN
5.5.6 Diagnosed Prevalent Cases of PDN
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines and Leading Prescribed Drugs
6.2.2 Clinical Practice
6.2.3 Non-pharmacological Treatments
6.3 US
6.4 5EU
6.5 Japan
7 Competitive Assessment
7.1 Overview
7.2 Nucynta ER/Palexia SR (tapentadol)
7.2.1 Overview
7.2.2 Efficacy
7.2.3 Safety
7.2.4 SWOT Analysis
7.2.5 Forecast
7.3 Lyrica (pregabalin)
7.3.1 Overview
7.3.2 Efficacy
7.3.3 Safety
7.3.4 SWOT Analysis
7.3.5 Forecast
7.4 Cymbalta (duloxetine)
7.4.1 Overview
7.4.2 Efficacy
7.4.3 Safety
7.4.4 SWOT Analysis
7.4.5 Forecast
7.5 Qutenza (8% capsaicin patch)
7.5.1 Overview
7.5.2 Efficacy
7.5.3 Safety
7.5.4 SWOT Analysis
7.5.5 Forecast
7.6 Tricyclic Antidepressants
7.6.1 Overview
7.6.2 Efficacy
7.6.3 Safety
7.6.4 SWOT Analysis
7.6.5 Forecast
7.7 Serotonin-Norepinephrine Reuptake Inhibitors
7.7.1 Overview
7.7.2 Efficacy
7.7.3 Safety
7.7.4 SWOT Analysis
7.7.5 Forecast
7.8 Anticonvulsants
7.8.1 Overview
7.8.2 Efficacy
7.8.3 Safety
7.8.4 SWOT Analysis
7.8.5 Forecast
7.9 Opioids
7.9.1 Overview
7.9.2 Efficacy
7.9.3 Safety
7.9.4 SWOT Analysis
7.9.5 Forecast
7.10 Non-Pharmacological Treatments
7.10.1 Overview
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Need for Drugs with an Improved Safety and Tolerability Profile
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Need for Drugs with an Improved Efficacy Profile
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Need for a Curative or Disease-Modifying Agent
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Need to Improve Physician and Public Recognition of PDN
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity
9 Pipeline Assessment
9.1 Overview
9.2 Clinical Trial Mapping
9.2.1 Clinical Trials by Country
9.3 Promising Drugs in Clinical Development
9.4 Mirogabalin Besylate
9.4.1 Overview
9.4.2 Efficacy
9.4.3 Safety
9.4.4 SWOT Analysis
9.4.5 Dosing and Formulation
9.4.6 Potential Clinical and Commercial Positioning
9.4.7 Forecast
9.5 VM202
9.5.1 Overview
9.5.2 Efficacy
9.5.3 Safety
9.5.4 SWOT Analysis
9.5.5 Dosing and Formulation
9.5.6 Potential Clinical and Commercial Positioning
9.5.7 Forecast
9.6 AmiKet
9.6.1 Overview
9.6.2 Efficacy
9.6.3 Safety
9.6.4 SWOT Analysis
9.6.5 Dosing and Formulation
9.6.6 Potential Clinical and Commercial Positioning
9.6.7 Forecast
9.7 MR309
9.7.1 Overview
9.7.2 Efficacy
9.7.3 Safety
9.7.4 SWOT Analysis
9.7.5 Dosing and Formulation
9.7.6 Potential Clinical and Commercial Positioning
9.7.7 Forecast
9.8 Cebranopadol
9.8.1 Overview
9.8.2 Efficacy
9.8.3 Safety
9.8.4 SWOT Analysis
9.8.5 Dosing and Formulation
9.8.6 Potential Clinical and Commercial Positioning
9.8.7 Forecast
9.9 Off Label Drugs in Development
9.10 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Pfizer
10.3.1 Overview
10.3.2 Portfolio Assessment
10.4 Grunethal
10.4.1 Overview
10.4.2 Portfolio Assessment
10.5 Daiichi-Sankyo
10.5.1 Overview
10.5.2 Portfolio Assessment
10.6 Depomed
10.6.1 Overview
10.6.2 Portfolio Assessment
10.7 ViroMed
10.7.1 Overview
10.7.2 Portfolio Assessment
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers-Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research-KOLs Interviewed for This Report
12.5 Primary Research-Payers Interviewed for This Report
12.6 Primary Research-Prescriber Survey
12.7 About the Authors
12.7.1 Analyst
12.7.2 Therapy Area Director
12.7.3 Epidemiologist
12.7.4 Managing Epidemiologist
12.7.5 Global Director of Therapy Analysis and Epidemiology
12.7.6 Global Head and EVP of Healthcare Operations and Strategy
12.8 About GlobalData
12.9 Contact Us
12.10 Disclaimer
Research Methodology
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.